Revenue
2022
2023
2024
2025
Pyxis Oncology, Inc. (PYXS)
Price$2.90Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $13.9M | $16.1M | $0 | $0 | — | — |
| Gross profit | $11.5M | $15.7M | $0 | — | — | — |
| Gross margin | 82.77% | 97.06% | — | — | — | — |
| Research & development | $73.7M | $58.7M | $49.6M | $86.1M | $51.1M | $9.0M |
| Operating expenses | $95.9M | $105.1M | $82.2M | $123.5M | $69.7M | $12.9M |
| Operating income | −$84.4M | −$89.5M | −$82.2M | −$123.5M | −$69.7M | −$12.9M |
| Operating margin | −609.18% | −554.07% | — | — | — | — |
| EBITDA | −$79.9M | −$86.5M | −$80.3M | −$122.8M | −$69.1M | −$12.4M |
| EBITDA margin | −576.63% | −535.60% | — | — | — | — |
| Net income | −$79.6M | −$77.3M | −$73.8M | −$120.7M | −$76.0M | −$12.8M |
| Net profit margin | −574.55% | −478.95% | — | — | — | — |
| Basic EPSper basic share | -$1.28 | -$1.32 | -$1.85 | -$3.65 | -$8.95 | -$12.45 |
| Diluted EPSper diluted share | -$1.28 | -$1.32 | -$1.85 | -$3.65 | -$8.95 | -$12.45 |
Owners
Reported shareholders
15.80%of listed shares
GordonMD Global Investments LP10.02M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
GordonMD Global Investments LP | 15.80%10.02M shares |
Pfizer Inc | 11.09%7.03M shares |
Laurion Capital Management LP | 7.73%4.9M shares |
Connealy Pamela Ann | ≈3.65%2.31M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.27%2.08M shares |
Atle Fund Management AB | 1.52%966.46K shares |
BlackRock, Inc. | 1.37%867.93K shares |
Palo Alto Investors LP | 1.36%864.28K shares |
MARSHALL WACE, LLP | 1.31%830.54K shares |
RENAISSANCE TECHNOLOGIES LLC | 1.22%772.23K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.93%591.85K shares |
Woodline Partners LP | 0.83%524K shares |
Wadhane Jitendra | ≈0.81%512.88K shares |
683 Capital Management, LLC | 0.72%459.37K shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 0.68%428.61K shares |
Longaeva Partners L.P. | 0.56%353.58K shares |
Decheng Capital LLC | 0.52%326.81K shares |
VANGUARD FIDUCIARY TRUST CO | 0.48%302.99K shares |
JANE STREET GROUP, LLC | 0.46%290.09K shares |
STATE STREET CORP | 0.39%248.84K shares |
Percentages use 63.43M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 21, 2025Form 4 · 10b5-1 | HUMPHREY RACHELDirector | SellCommon Stock | 13.9K | $1.03 | $14.3K | 81.3K |
| Apr 17, 2025Form 4 · 10b5-1 | HUMPHREY RACHELDirector | SellCommon Stock | 200 | $0.97 | $194.00 | 95.2K |
| Apr 14, 2025Form 4 · 10b5-1 | HUMPHREY RACHELDirector | SellCommon Stock | 1.4K | $0.97 | $1.4K | 95.4K |
| Nov 26, 2024Form 4 | Connealy Pamela AnnCFO & COO | BuyCommon Stock · indirect | 83.4K | $1.96 | $163.5K | 1.20M |
| Nov 26, 2024Form 4 | Connealy Pamela AnnCFO & COO | BuyCommon Stock · indirect | 5.5K | $2.00 | $10.9K | 1.12M |